The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
|Articles|October 6, 2015
bottelpack® 430 – compact blow-fill-seal technology
The bottelpack® 430 is a compact blow-fill-seal installation with one mould for the production of ampoules in PE, PP or other resins. It is ideal for small batch sizes.
Advertisement
What is expected from a compact and flexible laboratory BFS machine? On the one hand, there was the requirement to build a compact machine with a minimal mould size to keep the costs for trials and stability tests, etc. with various mould tools low. On the other hand, such a machine should utilize the advantages provided by the rotation machine technology (continuous parison, little plastic waste) of the popular bottelpack® 460/461 models. The result of this mix is the bp430 – a combined shuttle and rotation machine. The basic principle of the rotation machine technology with a continuous, extruded, uncut parison forms the basis for this machine. The mould follows the continuously extruded parison during the blow-fill-seal process. Once the mould has been opened, it cycles back and is positioned directly above the recently produced ampoule bar to shape the next block. This creates a continuous ampoule strip that is fed into an external punch. The bottelpack® 430 is ideal as a laboratory machine and also for small batch sizes. The filling system features state-of-the-art servo motors, an ergonomic design, easy operation and is also equipped with a dark/white separation design.
Contact Details:
rommelag ag
Website:
E-mail:
Advertisement
Related to this article
Florin Muraru, Gourav Pandey, and Richard Jaenisch explain where human sign-off belongs as multi-agent AI and document-parsing models reach GxP.
In this episode of Ask the Expert, Siegfried Schmitt, PhD, vice president, Technical at Parexel, and Susan J. Schniepp, distinguished fellow at Nelson Labs, discuss how companies should approach post-approval changes to their CMC regulatory filings.
The EC has approved AstraZeneca's Trixeo Aerosphere as the first single-inhaler triple-combination therapy for asthma in the EU, based on phase e data showing improved lung function and fewer severe exacerbations in patients uncontrolled on standard ICS/LABA treatment.
In this episode of Pharma Fundamentals, Dr. Aleksandra Zuraw, senior veterinary pathologist at Charles River, provides an introduction to the use of digital pathology in drug development.
Swedish biotech companies have a broad and varied product pipeline that is attracting attention from venture capitalists and pharmaceutical companies.
The agency issued a direct final rule that supports the use of innovative testing methods to limit the use of animals and maintain existing safety standards.
Jaenisch, Muraru, and Pandey debate whether AI "slop" is infiltrating pharma SOPs and deviation reports and who should catch it first.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
EU Clears AstraZeneca's Trixeo for Asthma, Opening New Manufacturing Demand for Single-Inhaler Triple Therapy
2
The FDA Finalizes Rule Recognizing Non-Animal Testing Methods, Building on Year-Long Reduction Push
3
Weekly Basal Insulin Efsitora: A New Biologics CMC Benchmark
4
PharmTech AI Pulse Check: Fixing AI Slop at the Source
5